India is under fresh scrutiny for exporting potent opioid medicines, particularly tapentadol, to West Africa. Reports suggest that millions of these tablets, produced by Indian pharmaceutical companies, are contributing to a rising addiction crisis in the region.
Despite India’s regulatory efforts, large shipments of high-strength tapentadol have reportedly reached countries like Nigeria, Sierra Leone, and Ghana. Some officials in these nations claim that many of the opioids are unapproved or illegal.
Dr. Tamorish Kole, a noted health expert, pointed out that while tapentadol is legally required for moderate to severe pain relief, concerns have led to stricter controls. “India banned the tapentadol–carisoprodol combination in 2025 due to its abuse potential in West Africa,” he said.
This situation raises serious questions about India’s reputation as the “pharmacy of the world.” Dr. Rajan Sharma, former president of the Indian Medical Association, noted that these allegations could tarnish India’s image in global pharmaceuticals and trigger tighter scrutiny from international authorities. “If companies are exploiting weaker regulatory frameworks in poorer countries, it would harm India’s credibility,” he warned.
Investigations have revealed that some shipments were misleadingly labeled as “harmless medicines.” These consignments were traced back to firms in Gujarat and Madhya Pradesh.
In response to international criticism, India adopted a “zero-tolerance” policy for illegal pharmaceutical exports in 2025. The Central Drugs Standard Control Organisation (CDSCO) announced plans to revoke export clearances for drugs not approved by importing countries.
However, Dr. Sharma expressed concerns about enforcement gaps. He highlighted that, while India has a solid regulatory framework, better coordination between central and state regulators is essential for stricter oversight of high-risk medicines.
Meanwhile, African governments are increasingly worried about the abuse of tapentadol, particularly among young people and laborers. In Nigeria and Sierra Leone, health authorities reported that the drug is being mixed into dangerous street narcotics, amplifying addiction and fatal overdoses.
This situation is vital to monitor as it reflects broader issues in global health and regulatory practices. Tracking the misuse of pharmaceuticals can shed light on significant public health challenges that transcend borders.
For those interested in exploring more about this crisis, recent reports highlight similar patterns in other regions, emphasizing the importance of responsible pharmaceutical distribution.
Source link
OPIOID, WEST AFRICA, AFRICA REGULATORY CONCERNS, INDIAN OPIOID EXPORTS, INDIAN OPIOID EXPORTS TO AFRICA RAISE REGULATORY CONCERNS FOR NEW DELHI
